The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen ’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung cancer that has worsened despite chemotherapy.
Amgen said the U.S. price for Imdelltra is $31,500 for the first cycle, and $30,000 for additional infusions. For a year of treatment, the price would come to $781,500. The disease, which is diagnosed in about 35,000 U.S. patients annually, is “one of most rapidly proliferating and most aggressive cancers there is,” Jay Bradner, Amgen’s chief scientific officer, said in an interview ahead of the decision.
Source: Healthcare Press (healthcarepress.net)
Cell Cancer Tarlatamab Cent Drug Price Imdelltra Amgen American Cancer Society New England Journal Of Medicine
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Amgen Drug Wins US Approval for Advanced Small Cell Lung CancerAmgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly needed new option for patients when chemotherapy stops working.
Source: BNNBloomberg - 🏆 83. / 50 Read more »
Investors Pile Into Amgen in Search of Next Obesity Drug PayoutInvestors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.
Source: BNNBloomberg - 🏆 83. / 50 Read more »
Amgen's peek at its GLP-1 drug trial results heightens competition in obesity marketCompetition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »
The two ways Amgen's new weight-loss drug can stand outPharmaceutical stock Amgen (AMGN) is rising following early positive results from the development of its new GLP-1 weight-loss drug, MariTide. Yahoo Finance ...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »
Amgen surges over confidence in early obesity drug resultsShares of Amgen (AMGN) are jumping Friday morning after the company showed confidence in early results from a GLP-1 weight-loss drug that is in development...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug dataExplore stories from Atlantic Canada.
Source: SaltWire Network - 🏆 45. / 63 Read more »